A One-Time Intervention for Type 2 Diabetes

Healthcare professionals

The DIAMOND (Tantalus) System is CE marked and available for commercial use. The DIAMOND II System is not CE marked currently.

Over 200 million people may benefit from our therapy

Type 2 diabetes already affects over 400 million people, of which 60% are obese. DIAMOND is an alternative to injectable therapies (insulin, GLP-1 agonists and others) intended to treat obese type 2 diabetes patients who are resistant to oral medication.
DIAMOND will improve the lives of millions of people.

Current solutions

Patients under insulin, or other injectable medication, face a variety of challenges affecting their day-to-day life. Often two or more daily blood sugar tests are needed and some patients may require four or more injections per day.

Common side effects and complications of insulin therapy include weight gain, hypertension and, in severe cases, hypoglycemia shocks requiring hospitalization. Additionally, many patients cannot tolerate GLP-1 agonist therapy due to nausea, vomiting and other gastrointestinal disturbances. These challenges ultimately lead to a lower compliance rate, further complications and increased healthcare costs.

Treating diabetes with a single intervention

DIAMOND therapy is as effective as insulin, but avoids the associated challenges and side effects. How does it work?

A small pacemaker-like device is implanted under the abdominal skin and connected by electrodes to the stomach, in a minimally invasive procedure. The device automatically detects when eating begins and sends gentle pulse signals (gastric contractility modulation signals, or GCM) to the stomach muscles.

As a result, the DIAMOND restores the physiological synchronization between food intake and natural hormone secretion, and lowers post meal glucose levels. Additionally, GCM signals cause an earlier satiation effect resulting in sustained weight loss. The DIAMOND therapy is completely reversible and does not affect the physiology of the body.

Improved glucose levels

  • HbA1c reduction of 1%
  • Sustained long term results
  • >300 patients treated in clinical studies,
    >8 years clinical experience

Freedom from insulin

  • DIAMOND is a one-time intervention
  • Does not cause hypoglycemia
  • No daily needles, no compliance issues

Natural pathways treatment

  • Minimal side effects
  • Fully reversible treatment
  • Sustained and significant weight loss
    and blood pressure reduction

Implantable device

The DIAMOND (Tantalus) System is CE marked and available for commercial use. The DIAMOND II System is not CE marked currently.

This small pulse generator is implanted under the abdominal skin and connected with leads to the stomach to deliver the DIAMOND therapy. The device is only 30 cc in volume and allows wireless recharging. It can be used for up to 15 years before a replacement is needed.

DIAMOND has received CE mark and is approved for sale in Europe, Australia and other international markets. DIAMOND is not approved for use in the USA.

Physician tablet

The tablet is used by certified physicians to set and control the therapy parameters of the implantable device through a wireless interface.

Image used for illustrative purposes only, actual tablet model may vary.

Patient charger

This external device is used to charge the implanted device wirelessly once a week by the patient at home. Charging time is around 45 minutes.

Over 300 patients treated in clinical trials


improved their glycemic control


experienced weight reduction

3 Years2

observation period in our long-term study


  • HbA1c reduction of 1%

  • Significant and sustained results over several years

  • Sustained weight loss of 5 – 10Kg and significant reduction of blood pressure by 10 mmHg


  • Safe implantation procedure

  • Does not cause hypoglycemia

  • Minimal side effects

Our clinical data

[1] Lebovitz H.E., Zalewski M., Gastric Electrical Stimulation (GES) in T2DM Improves Long-term Glycemic Control Through a Triglyceride-dependent Mechanism; Abstract # OP-0078. Presented at the IDF World Diabetes Congress Melbourne 2013, December 3, 2013, Melbourne. [2] Lebovitz HE, Ludvik B, Yaniv I, et al. Treatment of Patients with Obese Type 2 Diabetes with Tantalus-DIAMOND® Gastric Electrical Stimulation: Normal Triglycerides Predict Durable Effects for at Least 3 Years. Horm Metab Res. 2015;47(6):456-62. [3] Wong SK, Kong AP, Luk AO, et al. A pilot study to compare meal-triggered gastric electrical stimulation and insulin treatment in Chinese obese type 2 diabetes. Diabetes Technol Ther. 2015;17(4):283-90. [4] Lebovitz HE, Ludvik B, Kozakowski J, et al. Gastric electrical stimulation treatment of type 2 diabetes: effects of implantation versus meal-mediated stimulation. A randomized blinded cross-over trial. Physiol Rep. 2015;3(7). [5] Lebovitz HE, Ludvik B, Yaniv I, et al. Fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm. Diabet Med. 2013;30(6):687-93. [6] Bohdjalian A, Prager G, Rosak C, et al. Improvement in glycemic control in morbidly obese type 2 diabetic subjects by gastric stimulation. Obes Surg. 2009;19(9):1221-7. [7] Sanmiguel CP, Conklin JL, Cunneen SA, et al. Gastric electrical stimulation with the TANTALUS System in obese type 2 diabetes patients: effect on weight and glycemic control. J Diabetes Sci Technol. 2009;3(4):964-70. [8] Bohdjalian A, Prager G, Aviv R, et al. One-year experience with Tantalus: a new surgical approach to treat morbid obesity. Obes Surg. 2006;16(5):627-34.